Literature DB >> 19815504

Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge.

Randall J Brezski1, Omid Vafa, Diane Petrone, Susan H Tam, Gordon Powers, Mary H Ryan, Jennifer L Luongo, Allison Oberholtzer, David M Knight, Robert E Jordan.   

Abstract

The successful elimination of pathogenic cells and microorganisms by the humoral immune system relies on effective interactions between host immunoglobulins and Fc gamma receptors on effector cells, in addition to the complement system. Essential Ig motifs that direct those interactions reside within the conserved IgG lower hinge/CH2 interface. We noted that a group of tumor-related and microbial proteases cleaved human IgG1s in that region, and the "nick" of just one of the heavy chains profoundly inhibited IgG1 effector functions. We focused on IgG1 monoclonal antibodies (mAbs) since IgG1 is the most abundant human subclass and demonstrates robust Fc-mediated effector functions. The loss of Fc-mediated cell killing activities was correlated with diminished binding to the Fc gamma family of receptors, but a similar decrease in affinity was not observed toward the FcRn receptor that maintains IgG in circulation. Endogenous human IgG cleavage products of comparable size to mAbs with the single cleavage were detected by Western blot analysis in synovial fluid from patients with rheumatoid arthritis and in breast carcinoma extracts. Their detection is problematic under physiological conditions, since there is no loss of structure, and antigen-binding capability is unaffected. These findings suggest that within the hostile proteolytic microenvironments associated with many diseases, key effector functions of host IgGs, or therapeutic Abs, may be compromised.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19815504      PMCID: PMC2758810          DOI: 10.1073/pnas.0904174106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

1.  The structure of a human type III Fcgamma receptor in complex with Fc.

Authors:  S Radaev; S Motyka; W H Fridman; C Sautes-Fridman; P D Sun
Journal:  J Biol Chem       Date:  2001-01-31       Impact factor: 5.157

2.  The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A.

Authors:  B D Wines; M S Powell; P W Parren; N Barnes; P M Hogarth
Journal:  J Immunol       Date:  2000-05-15       Impact factor: 5.422

3.  Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin.

Authors:  Andrew J H Gearing; Susan J Thorpe; Karen Miller; Matthew Mangan; Paul G Varley; Tim Dudgeon; George Ward; Christina Turner; Robin Thorpe
Journal:  Immunol Lett       Date:  2002-04-01       Impact factor: 3.685

4.  High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

Authors:  R L Shields; A K Namenuk; K Hong; Y G Meng; J Rae; J Briggs; D Xie; J Lai; A Stadlen; B Li; J A Fox; L G Presta
Journal:  J Biol Chem       Date:  2000-11-28       Impact factor: 5.157

5.  Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies.

Authors:  R J Ober; C G Radu; V Ghetie; E S Ward
Journal:  Int Immunol       Date:  2001-12       Impact factor: 4.823

6.  Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment.

Authors:  C Ribbens; M Martin y Porras; N Franchimont; M-J Kaiser; J-M Jaspar; P Damas; F A Houssiau; M G Malaise
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

7.  IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G.

Authors:  Ulrich von Pawel-Rammingen; Björn P Johansson; Lars Björck
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

8.  Matrix metalloproteinases: biologic activity and clinical implications.

Authors:  A R Nelson; B Fingleton; M L Rothenberg; L M Matrisian
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

9.  Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis.

Authors:  R William Vandivier; Valerie A Fadok; Peter R Hoffmann; Donna L Bratton; Churee Penvari; Kevin K Brown; Joseph D Brain; Frank J Accurso; Peter M Henson
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

10.  M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.

Authors:  Marzia Leidi; Elisa Gotti; Luca Bologna; Elena Miranda; Monica Rimoldi; Antonio Sica; Massimo Roncalli; Giuseppe A Palumbo; Martino Introna; Josée Golay
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

View more
  35 in total

1.  Improved stability of multivalent antibodies containing the human collagen XV trimerization domain.

Authors:  Angel M Cuesta; David Sánchez-Martín; Ana Blanco-Toribio; Maider Villate; Kelly Enciso-Álvarez; Ana Alvarez-Cienfuegos; Noelia Sainz-Pastor; Laura Sanz; Francisco J Blanco; Luis Alvarez-Vallina
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  Galactosylation variations in marketed therapeutic antibodies.

Authors:  T Shantha Raju; Robert E Jordan
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

3.  A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.

Authors:  Randall J Brezski; Michelle Kinder; Katharine D Grugan; Keri L Soring; Jill Carton; Allison R Greenplate; Theodore Petley; Dorie Capaldi; Kerry Brosnan; Eva Emmell; Sharon Watson; Robert E Jordan
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

4.  Structural features of bovine colostral immunoglobulin that confer proteolytic stability in a simulated intestinal fluid.

Authors:  Randall E Burton; Skaison Kim; Rutvij Patel; Deborah S Hartman; Daniel E Tracey; Barbara S Fox
Journal:  J Biol Chem       Date:  2020-07-14       Impact factor: 5.157

Review 5.  Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis.

Authors:  Leendert A Trouw; Theo Rispens; Rene E M Toes
Journal:  Nat Rev Rheumatol       Date:  2017-03-09       Impact factor: 20.543

6.  Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA.

Authors:  Juan Carlos Almagro; Gary L Gilliland; Felix Breden; Jamie K Scott; Devin Sok; Matthias Pauthner; Janice M Reichert; Gustavo Helguera; Raiees Andrabi; Robert Mabry; Mathieu Bléry; James E Voss; Juha Laurén; Lubna Abuqayyas; Stefan Barghorn; Eshel Ben-Jacob; James E Crowe; James S Huston; Stephen Albert Johnston; Eric Krauland; Fridtjof Lund-Johansen; Wayne A Marasco; Paul W H I Parren; Kai Y Xu
Journal:  MAbs       Date:  2014-03-03       Impact factor: 5.857

7.  Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1.

Authors:  M C Holland; J U Wurthner; P J Morley; M A Birchler; J Lambert; M Albayaty; A P Serone; R Wilson; Y Chen; R M Forrest; J C Cordy; D A Lipson; A I Bayliffe
Journal:  J Clin Immunol       Date:  2013-07-06       Impact factor: 8.317

8.  Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application schedule.

Authors:  Michael Dobosz; Ute Haupt; Werner Scheuer
Journal:  MAbs       Date:  2016-09-23       Impact factor: 5.857

Review 9.  Interaction of host and Staphylococcus aureus protease-system regulates virulence and pathogenicity.

Authors:  Vigyasa Singh; Ujjal Jyoti Phukan
Journal:  Med Microbiol Immunol       Date:  2018-11-27       Impact factor: 3.402

10.  Tumor evasion of humoral immunity mediated by proteolytic impairment of antibody triggered immune effector function.

Authors:  Ningyan Zhang; Robert E Jordan; Zhiqiang An
Journal:  Oncoimmunology       Date:  2015-12-29       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.